Cadrenal Therapeutics Inc

Cadrenal Therapeutics, Inc. is a biopharmaceutical company focused on developing transformative therapeutics to overcome the gaps in anticoagulation therapy. The Company’s lead investigational product is tecarfarin, a novel oral vitamin K antagonist anticoagulant that is designed to address unmet needs in anticoagulation therapy. Tecarfarin is a reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Tecarfarin has orphan drug designation (ODD) for advanced heart failure patients with implanted mechanical circulatory support devices, including left ventricular assisted devices (LVADs). The Company also has ODD and fast-track status for tecarfarin in end-stage kidney disease and atrial fibrillation (ESKD+AFib). It also includes Frunexian, a Phase 2-ready IV Factor XIa agent for acute anticoagulation and EP-7327 is a ready oral small molecule candidate for chronic indications.